摘要
[摘要 ] 目的 探讨培美曲塞联合常规化疗在Ⅲ～Ⅳ期非小细胞肺癌患者中的应用价值。方法 在该医院 2017年 1月— 2019年 12月期间诊治的Ⅲ～Ⅳ期非小细胞肺癌患者中方便选取 40例予以化学治疗：将接受常规化疗（多西他赛联合顺铂）者设为对照组（ n=20），而接受培美曲塞联合常规化疗（培美曲塞联合顺铂）者设为研究组（ n=20），比较两组患者化疗效果、血清肿瘤标志物差异。 结果 ①研究组患者近期肿瘤控制率 45.00%高于对照组的 10.00%（ χ2=5.177， P=0.023） ;②治疗后，研究组 CEA、 CYFRA21-1水平均低于对照组（ t=6.791、 11.210， P=0.000）。 结论 培美曲塞联合常规化疗在Ⅲ～Ⅳ期非小细胞肺癌患者中的应用价值显著，可优化近期化疗效果，并改善其肿瘤血清标志物指标，值得借鉴。 [关键词 ] 培美曲塞 ;Ⅲ～Ⅳ期 ;非小细胞肺癌 ;血清肿瘤标志物 [Abstract] Objective To explore the application value of pemetrexed combined with conventional chemotherapy in patients with stage Ⅲ - Ⅳ non-small cell lung cancer. Method 40 patients with stage Ⅲ to Ⅳ NSCLC diagnosed and treated in the hospital from January 2017 to December 2019 were conveniently selected for chemotherapy: those who received conventional chemotherapy (docetaxel combined with cisplatin) were set as the control group (n = 20), while those who received pemetrexed combined with conventional chemotherapy (pemetrexed combined with cisplatin) were set as the study group (n = 20), and the chemotherapy effect and blood volume of the two groups were compared Clear the difference of tumor markers. Results ① the recent tumor control rate in the study group was 45.00% higher than that in the control group (χ 2 = 5.177, P = 0.023); ② after treatment, CEA and CYFRA21-1 levels in the study group were lower than those in the control group (t = 6.791, 11.210, P = 0.000). Conclusion pemetrexed combined with conventional chemotherapy has significant application value in patients with stage Ⅲ to Ⅳ non-small cell lung cancer. It can optimize the short-term chemotherapy effect and improve the tumor serum markers.
出版日期
2020年04月20日（中国Betway体育网页登陆平台首次上网日期，不代表论文的发表时间）
